sentence
stringlengths 27
1.01k
| drug1
stringlengths 2
46
| drug2
stringlengths 2
63
| relation
stringclasses 5
values | source_file
stringclasses 566
values | sentence_id
stringlengths 17
21
| pair_id
stringlengths 20
26
|
|---|---|---|---|---|---|---|
Anticonvulsants: In a pharmacokinetic study, maximum plasma concentrations of felodipine were considerably lower in epileptic patients on long-term anticonvulsant therapy (eg, phenytoin, carbamazepine, or phenobarbital) than in healthy volunteers.
|
felodipine
|
anticonvulsant
|
MECHANISM
|
Felodipine_ddi.xml
|
DDI-DrugBank.d316.s14
|
DDI-DrugBank.d316.s14.p5
|
Central Nervous System Depressants: The concomitant use of DURAGESIC (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.
|
opioids
|
sedatives
|
NONE
|
Fentanyl_ddi.xml
|
DDI-DrugBank.d170.s5
|
DDI-DrugBank.d170.s5.p42
|
Dexamethasone at 10(-10) M or retinyl acetate at about 3 X 10(-9) M inhibits proliferation stimulated by EGF.
|
retinyl acetate
|
EGF
|
EFFECT
|
3881461.xml
|
DDI-MedLine.d12.s3
|
DDI-MedLine.d12.s3.p2
|
The potential for drug interactions with EMTRIVA has been studied in combination with indinavir, stavudine, famciclovir, and tenofovir disoproxil fumarate.
|
indinavir
|
tenofovir disoproxil fumarate
|
NONE
|
Emtricitabine_ddi.xml
|
DDI-DrugBank.d375.s0
|
DDI-DrugBank.d375.s0.p6
|
Avoid the use of preparations such as decongestants and local anesthetics which contain any sympathomimetic amine (e.g., epinephrine, norepinephrine), since it has been reported that tricyclic antidepressants can potentiate the effects of catecholamines.
|
sympathomimetic amine
|
tricyclic antidepressants
|
ADVISE
|
Imipramine_ddi.xml
|
DDI-DrugBank.d77.s2
|
DDI-DrugBank.d77.s2.p11
|
The effect of TORADOL on plasma lithium has not been studied, but cases of increased lithium plasma levels during TORADOL therapy have been reported.
|
lithium
|
TORADOL
|
MECHANISM
|
Ketorolac_ddi.xml
|
DDI-DrugBank.d3.s12
|
DDI-DrugBank.d3.s12.p5
|
The co-administration of Natrecor with IV vasodilators such as nitroglycerin, nitroprusside, milrinone, or IV ACE inhibitors has not been evaluated (these drugs were not co-administered with Natrecor in clinical trials).
|
vasodilators
|
milrinone
|
NONE
|
Nesiritide_ddi.xml
|
DDI-DrugBank.d239.s2
|
DDI-DrugBank.d239.s2.p8
|
Iodine or iodine excess may decrease the effect of Carbimazole, and an iodine deficiency can increase the effect of Carbimazole.
|
Iodine
|
Carbimazole
|
EFFECT
|
Carbimazole_ddi.xml
|
DDI-DrugBank.d213.s0
|
DDI-DrugBank.d213.s0.p1
|
Probenecid: Concomitant administration of TORADOL ORAL and probenecid resulted in decreased clearance of ketorolac and significant increases in ketorolac plasma levels (total AUC increased approximately threefold from 5.4 to 17.8 m g/h/mL) and terminal half-life increased approximately twofold from 6.6 to 15.1 hours.
|
TORADOL
|
probenecid
|
MECHANISM
|
Ketorolac_ddi.xml
|
DDI-DrugBank.d3.s9
|
DDI-DrugBank.d3.s9.p4
|
In patients with mild to moderate hypertension, administration of 25 mg daily of VIOXX with the ACE inhibitor benazepril, 10 to 40 mg for 4 weeks, was associated with an average increase in mean arterial pressure of about 3 mm Hg compared to ACE inhibitor alone.
|
VIOXX
|
benazepril
|
EFFECT
|
Rofecoxib_ddi.xml
|
DDI-DrugBank.d210.s1
|
DDI-DrugBank.d210.s1.p1
|
Misonidazole protects mouse tumour and normal tissues from the toxicity of oral CCNU.
|
Misonidazole
|
CCNU
|
EFFECT
|
3966974.xml
|
DDI-MedLine.d85.s0
|
DDI-MedLine.d85.s0.p0
|
Corticosteroids, Methylxanthines and Diuretics: Concomitant treatment with xanthine derivatives, steroids, or diuretics may potentiate a possible hypokalemic effect of beta2-agonists.
|
xanthine derivatives
|
beta2-agonists.
|
EFFECT
|
Formoterol_ddi.xml
|
DDI-DrugBank.d103.s4
|
DDI-DrugBank.d103.s4.p17
|
Animal experience indicates that clorazepate dipotassium prolongs the sleeping time after hexobarbital or after ethyl alcohol, increases the inhibitory effects of chlorpromazine, but does not exhibit monoamine oxidase inhibition.
|
clorazepate dipotassium
|
hexobarbital
|
EFFECT
|
Clorazepate_ddi.xml
|
DDI-DrugBank.d335.s1
|
DDI-DrugBank.d335.s1.p0
|
Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain narcotic analgesics such as meperidine, the phenothiazines and other antipsychotics, tricyclic antidepressants, certain antiarrhythmics such as the quinidine salts, and antihistamines.
|
AKINETON
|
phenothiazines
|
EFFECT
|
Biperiden_ddi.xml
|
DDI-DrugBank.d401.s0
|
DDI-DrugBank.d401.s0.p11
|
The steady state plasma concentrations of imipramine and desipramine have been reported to be increased an average of 31% and 20%, respectively, by the concomitant administration of alprazolam tablets in doses up to 4 mg/day.
|
imipramine
|
alprazolam
|
MECHANISM
|
Alprazolam_ddi.xml
|
DDI-DrugBank.d131.s1
|
DDI-DrugBank.d131.s1.p1
|
Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
|
clofibrate
|
oxyphenbutazone
|
NONE
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s87
|
DDI-DrugBank.d64.s87.p645
|
Conversely, the administration of STADOL NS (1 mg butorphanol QID) did not alter the pharmacokinetics of a 300-mg dose of cimetidine.
|
STADOL NS
|
butorphanol
|
NONE
|
Butorphanol_ddi.xml
|
DDI-DrugBank.d246.s11
|
DDI-DrugBank.d246.s11.p0
|
Aspirin: Concomitant administration of low-dose aspirin with VIOXX may result in an increased rate of GI ulceration or other complications, compared to use of VIOXX alone.
|
aspirin
|
VIOXX
|
EFFECT
|
Rofecoxib_ddi.xml
|
DDI-DrugBank.d210.s3
|
DDI-DrugBank.d210.s3.p3
|
Aprepitant increased the AUC of midazolam by 25% on Day 4 and decreased the AUC of midazolam by 19% on Day 8 relative to the dosing of Aprepitant on Days 1 through 3.
|
Aprepitant
|
midazolam
|
MECHANISM
|
Aprepitant_ddi.xml
|
DDI-DrugBank.d382.s25
|
DDI-DrugBank.d382.s25.p0
|
Cimetidine reduces the clearance of ALFENTA.
|
Cimetidine
|
ALFENTA
|
MECHANISM
|
Alfentanil_ddi.xml
|
DDI-DrugBank.d8.s4
|
DDI-DrugBank.d8.s4.p0
|
Adrenergic blockers Adrenergic blockers are inhibited by amphetamines.
|
Adrenergic blockers
|
amphetamines
|
EFFECT
|
Lisdexamfetamine_ddi.xml
|
DDI-DrugBank.d158.s2
|
DDI-DrugBank.d158.s2.p2
|
There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.
|
erythromycin
|
cyclosporine
|
INT
|
Erythromycin_ddi.xml
|
DDI-DrugBank.d397.s8
|
DDI-DrugBank.d397.s8.p1
|
During clinical trials, iloprost was used concurrently with anticoagulants, diuretics, cardiac glycosides, calcium channel blockers, analgesics, antipyretics, nonsteroidal antiinflammatories, corticosteroids, and other medications.
|
diuretics
|
cardiac glycosides
|
NONE
|
Iloprost_ddi.xml
|
DDI-DrugBank.d549.s3
|
DDI-DrugBank.d549.s3.p15
|
Ketoconazole: Ketoconazole may inhibit both synthetic and catabolic enzymes of vitamin D.
|
Ketoconazole
|
vitamin D
|
MECHANISM
|
Cholecalciferol_ddi.xml
|
DDI-DrugBank.d404.s8
|
DDI-DrugBank.d404.s8.p2
|
- Drugs whose efficacy is impaired by phenytoin include: anticoagulants, corticosteroids, coumarin, digitoxin, doxycycline, estrogens, furosemide, oral contraceptives, rifampin, quinidine, theophylline, vitamin D.
|
phenytoin
|
corticosteroids
|
EFFECT
|
Fosphenytoin_ddi.xml
|
DDI-DrugBank.d40.s19
|
DDI-DrugBank.d40.s19.p1
|
When initiating a multi-day course of grepafloxacin in a patient maintained on theophylline, the theophylline maintenance dose should be halved for the period of concurrent use of grepafloxacin and monitoring of serum theophylline concentrations should be initiated as a guide to further dosage adjustments.
|
theophylline
|
grepafloxacin
|
ADVISE
|
Grepafloxacin_ddi.xml
|
DDI-DrugBank.d78.s8
|
DDI-DrugBank.d78.s8.p7
|
Since acetaminophen in high doses has been associated with hepatotoxicity, concomitant administration of diflunisal and acetaminophen should be used cautiously, with careful monitoring of patients.
|
diflunisal
|
acetaminophen
|
ADVISE
|
Diflunisal_ddi.xml
|
DDI-DrugBank.d132.s13
|
DDI-DrugBank.d132.s13.p2
|
Amitriptyline in combination with clonidine enhances the manifestation of corneal lesions in rats Epidural Injection Clonidine may potentiate the CNS-depressive effect of alcohol, barbiturates or other sedating drugs.
|
Clonidine
|
sedating drugs
|
EFFECT
|
Clonidine_ddi.xml
|
DDI-DrugBank.d495.s2
|
DDI-DrugBank.d495.s2.p11
|
Limited clinical experience indicates that requirements for volatile inhalation anesthetics are reduced by 30 to 50% for the first sixty (60) minutes following ALFENTA induction The concomitant use of erythromycin with ALFENTA can significantly inhibit ALFENTA clearance and may increase the risk of prolonged or delayed respiratory depression.
|
erythromycin
|
ALFENTA
|
MECHANISM
|
Alfentanil_ddi.xml
|
DDI-DrugBank.d8.s3
|
DDI-DrugBank.d8.s3.p7
|
Phenobarbital: Coadministration of felbamate with phenobarbital causes an increase in phenobarbital plasma concentrations, In 12 otherwise healthy male volunteers ingesting phenobarbital, the steady-state trough (Cmin) phenobarbital concentration was 14.2 micrograms/mL.
|
Phenobarbital
|
phenobarbital
|
NONE
|
Felbamate_ddi.xml
|
DDI-DrugBank.d434.s28
|
DDI-DrugBank.d434.s28.p2
|
Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
|
EQUETROTM
|
itraconazole
|
MECHANISM
|
Carbamazepine_ddi.xml
|
DDI-DrugBank.d94.s11
|
DDI-DrugBank.d94.s11.p20
|
Cimetidine: In the presence of cimetidine at 300 mg QID (N=12) the mean apparent oral clearance of gabapentin fell by 14% and creatinine clearance fell by 10%.
|
cimetidine
|
gabapentin
|
MECHANISM
|
Gabapentin_ddi.xml
|
DDI-DrugBank.d438.s29
|
DDI-DrugBank.d438.s29.p2
|
Additive CNS depression may occur when antihistamines are administered concomitantly with other CNS depressants including barbiturates, tranquilizers, and alcohol.
|
antihistamines
|
alcohol
|
EFFECT
|
Clemastine_ddi.xml
|
DDI-DrugBank.d309.s0
|
DDI-DrugBank.d309.s0.p3
|
Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
|
antifungals
|
prednisolone
|
NONE
|
Etonogestrel_ddi.xml
|
DDI-DrugBank.d484.s0
|
DDI-DrugBank.d484.s0.p517
|
Pharmacokinetic studies have demonstrated that omeprazole and erythromycin significantly increased the systemic exposure of cilostazol and/or its major metabolites.
|
omeprazole
|
cilostazol
|
MECHANISM
|
Cilostazol_ddi.xml
|
DDI-DrugBank.d358.s1
|
DDI-DrugBank.d358.s1.p1
|
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
|
nondepolarizing agents
|
clindamycin
|
EFFECT
|
Cisatracurium Besylate_ddi.xml
|
DDI-DrugBank.d60.s12
|
DDI-DrugBank.d60.s12.p7
|
In the presence of ouabain (10(-5) M), PTX (10(-8) M) failed to cause the first contraction;
|
ouabain
|
PTX
|
EFFECT
|
2857198.xml
|
DDI-MedLine.d56.s2
|
DDI-MedLine.d56.s2.p0
|
Iodine or iodine excess may decrease the effect of Carbimazole, and an iodine deficiency can increase the effect of Carbimazole.
|
iodine
|
Carbimazole
|
EFFECT
|
Carbimazole_ddi.xml
|
DDI-DrugBank.d213.s0
|
DDI-DrugBank.d213.s0.p9
|
Anesthetics/Sedatives/Hypnotics/Opioids: Co-administration of PRECEDEX with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects.
|
PRECEDEX
|
opioids
|
EFFECT
|
Dexmedetomidine_ddi.xml
|
DDI-DrugBank.d197.s1
|
DDI-DrugBank.d197.s1.p29
|
Cyclosporine, tacrolimus and digoxin concentrations should be monitored at the initiation of Itraconazole therapy and frequently thereafter, and the dose of these three drug products adjusted appropriately.
|
tacrolimus
|
Itraconazole
|
ADVISE
|
Itraconazole_ddi.xml
|
DDI-DrugBank.d165.s16
|
DDI-DrugBank.d165.s16.p4
|
Dopamine-induced renal and mesenteric vasodilation is not antagonized by either alpha- or beta-adrenergic blocking agents.
|
alpha-adrenergic blocking agents
|
beta-adrenergic blocking agents
|
NONE
|
Dopamine_ddi.xml
|
DDI-DrugBank.d325.s6
|
DDI-DrugBank.d325.s6.p2
|
Antifungals: In vitro and/or in vivo data indicate that fluconazole, itraconazole, and oral ketoconazole markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.
|
cisapride
|
cisapride
|
NONE
|
Cisapride_ddi.xml
|
DDI-DrugBank.d237.s7
|
DDI-DrugBank.d237.s7.p14
|
Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
|
anticoagulant
|
quinidine
|
EFFECT
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s87
|
DDI-DrugBank.d64.s87.p41
|
Corticosteroids: Dexamethasone: Aprepitant, when given as a regimen of 125mg with dexamethasone coadministered orally as 20 mg on Day 1, and Aprepitant when given as 80 mg/day with dexamethasone coadministered orally as 8 mg on Days 2 through 5, increased the AUC of dexamethasone, a CYP3A4 substrate by 2.2-fold, on Days 1 and 5.
|
Aprepitant
|
dexamethasone
|
MECHANISM
|
Aprepitant_ddi.xml
|
DDI-DrugBank.d382.s9
|
DDI-DrugBank.d382.s9.p11
|
Two percent of patients treated concurrently with ENBREL and anakinra developed neutropenia (ANC 1 x 109/L).
|
ENBREL
|
anakinra
|
EFFECT
|
Etanercept_ddi.xml
|
DDI-DrugBank.d341.s3
|
DDI-DrugBank.d341.s3.p0
|
Probenecid or Cimetidine: Concomitant administration of probenecid or cimetidine decreases the elimination of zalcitabine, most likely by inhibition of renal tubular secretion of zalcitabine.
|
Cimetidine
|
probenecid
|
NONE
|
Zalcitabine_ddi.xml
|
DDI-DrugBank.d263.s20
|
DDI-DrugBank.d263.s20.p5
|
It is recommended to avoid concurrent administration of ethambutol with aluminum hydroxide containing antacids for at least 4 hours following ethambutol administration.
|
ethambutol
|
aluminum hydroxide
|
ADVISE
|
Ethambutol_ddi.xml
|
DDI-DrugBank.d160.s1
|
DDI-DrugBank.d160.s1.p0
|
These include probenecid, cholestyramine, and some antibiotics (e.g. erythromycin, rifamipicin, ampicillin and chloramphenicol).
|
cholestyramine
|
erythromycin
|
NONE
|
Entacapone_ddi.xml
|
DDI-DrugBank.d455.s10
|
DDI-DrugBank.d455.s10.p6
|
Although the occurrence has not been reported with Cefizox, nephrotoxicity has been reported following concomitant administration of other cephalosporins and aminoglycosides.
|
cephalosporins
|
aminoglycosides
|
EFFECT
|
Ceftizoxime_ddi.xml
|
DDI-DrugBank.d33.s0
|
DDI-DrugBank.d33.s0.p2
|
Cephalosporins-Cephalosporins containing side chains of N-methylthiotetrazole (cefmenoxime, cefoperazone, cefotetan, cefamandole, latamoxef) or methylthiadiazole (cefazolin) can cause vitamin K deficiency and hypoprothrombinemia.
|
cefamandole
|
cefazolin
|
NONE
|
Menadione_ddi.xml
|
DDI-DrugBank.d139.s1
|
DDI-DrugBank.d139.s1.p26
|
The elimination half life of midazolam and triazolam also increased (1.5-2.5 fold) during coadministration with diltiazem.
|
triazolam
|
diltiazem
|
MECHANISM
|
Diltiazem_ddi.xml
|
DDI-DrugBank.d565.s34
|
DDI-DrugBank.d565.s34.p2
|
Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
|
anticoagulant
|
glucagon
|
EFFECT
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s87
|
DDI-DrugBank.d64.s87.p20
|
A dose adjustment is not needed when zidovudine is administered with VIRACEPT.
|
zidovudine
|
VIRACEPT
|
ADVISE
|
Nelfinavir_ddi.xml
|
DDI-DrugBank.d340.s27
|
DDI-DrugBank.d340.s27.p0
|
In the experiments reported here, we examined the interactions between 1,25(OH)2D3 and the antiestrogen 4-hydroxytamoxifen (TAM), which also induces apoptosis in MCF-7 cells.
|
antiestrogen
|
TAM
|
NONE
|
7654327.xml
|
DDI-MedLine.d53.s3
|
DDI-MedLine.d53.s3.p4
|
Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).
|
Dexbrompheniramine
|
monoamine oxidase (MAO) inhibitors
|
EFFECT
|
Brompheniramine_ddi.xml
|
DDI-DrugBank.d192.s0
|
DDI-DrugBank.d192.s0.p5
|
Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.
|
sertraline
|
risperidone
|
NONE
|
Bupropion_ddi.xml
|
DDI-DrugBank.d5.s17
|
DDI-DrugBank.d5.s17.p93
|
- When Bezalip or Bezalip retard is used concurrently with anion-exchange resins (e.g. cholestryramine), an interval of at least 2 hours should be maintained between the two medicines, since the absorption of Bezalip or Bezalip retard is impaired
|
Bezalip retard
|
cholestryramine
|
ADVISE
|
Bezafibrate_ddi.xml
|
DDI-DrugBank.d291.s9
|
DDI-DrugBank.d291.s9.p6
|
However, the concomitant use of Argatroban and warfarin (5-7.5 mg initial oral dose followed by 2.5-6 mg/day orally for 6-10 days) results in prolongation of the prothrombin time (PT) and International Normalized Ratio (INR).
|
Argatroban
|
warfarin
|
EFFECT
|
Argatroban_ddi.xml
|
DDI-DrugBank.d148.s4
|
DDI-DrugBank.d148.s4.p0
|
Antacids: In a clinical pharmacology study, coadministration of an antacid (aluminum hydroxide, magnesium hydroxide, and simethicone) with fosinopril reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone, suggesting that antacids may impair absorption of fosinopril.
|
antacid
|
fosinopril
|
MECHANISM
|
Fosinopril_ddi.xml
|
DDI-DrugBank.d176.s9
|
DDI-DrugBank.d176.s9.p12
|
This interaction should be given consideration in patients taking CELEBREX concomitantly with ACE-inhibitors.
|
CELEBREX
|
ACE-inhibitors
|
ADVISE
|
Celecoxib_ddi.xml
|
DDI-DrugBank.d172.s10
|
DDI-DrugBank.d172.s10.p0
|
Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.
|
caffeine
|
anesthetics
|
EFFECT
|
Butalbital_ddi.xml
|
DDI-DrugBank.d559.s1
|
DDI-DrugBank.d559.s1.p19
|
Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, some azoles and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.
|
sulfonylureas
|
sulfonamides
|
EFFECT
|
Glipizide_ddi.xml
|
DDI-DrugBank.d225.s0
|
DDI-DrugBank.d225.s0.p3
|
Leukocyte transfusions: acute pulmonary toxicity has been reported in patients receiving intravenous amphotericin B and leukocyte transfusions.
|
amphotericin B
|
leukocyte transfusions
|
EFFECT
|
Amphotericin B_ddi.xml
|
DDI-DrugBank.d318.s14
|
DDI-DrugBank.d318.s14.p2
|
Amprenavir significantly increased the area under the curve at steady state (AUC(ss)) of rifabutin by 2.93-fold and the AUC(ss) of 25-O-desacetylrifabutin by 13.3-fold.
|
Amprenavir
|
25-O-desacetylrifabutin
|
MECHANISM
|
11158747.xml
|
DDI-MedLine.d3.s7
|
DDI-MedLine.d3.s7.p1
|
Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.
|
norfloxacin
|
TIKOSYN
|
ADVISE
|
Dofetilide_ddi.xml
|
DDI-DrugBank.d558.s25
|
DDI-DrugBank.d558.s25.p70
|
Diuretics: Diclofenac and other NSAIDs can inhibit the activity of diuretics.
|
NSAIDs
|
diuretics
|
EFFECT
|
Diclofenac_ddi.xml
|
DDI-DrugBank.d249.s14
|
DDI-DrugBank.d249.s14.p5
|
Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
|
delavirdine
|
itraconazole
|
NONE
|
Carbamazepine_ddi.xml
|
DDI-DrugBank.d94.s11
|
DDI-DrugBank.d94.s11.p449
|
Iron salts may reduce the bioavailability of carbidopa and levodopa.
|
Iron
|
levodopa
|
MECHANISM
|
Carbidopa_ddi.xml
|
DDI-DrugBank.d47.s5
|
DDI-DrugBank.d47.s5.p1
|
When carbamazepine is withdrawn from the combination therapy, aripiprazole dose should then be reduced.
|
carbamazepine
|
aripiprazole
|
ADVISE
|
Aripiprazole_ddi.xml
|
DDI-DrugBank.d509.s22
|
DDI-DrugBank.d509.s22.p0
|
Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and AXERT within 24 hours of each other should be avoided.
|
methysergide
|
AXERT
|
ADVISE
|
Almotriptan_ddi.xml
|
DDI-DrugBank.d299.s1
|
DDI-DrugBank.d299.s1.p9
|
- Antihypertensives: Bumetanide may potentiate the effect of various antihypertensive drugs, necessitating a reduction in the dosage of these drugs.
|
Bumetanide
|
antihypertensive drugs
|
EFFECT
|
Bumetanide_ddi.xml
|
DDI-DrugBank.d331.s9
|
DDI-DrugBank.d331.s9.p2
|
- Although not a true drug interaction, tricyclic antidepressants may precipitate seizures in susceptible patients and Cerebyx dosage may need to be adjusted
|
tricyclic antidepressants
|
Cerebyx
|
EFFECT
|
Fosphenytoin_ddi.xml
|
DDI-DrugBank.d40.s17
|
DDI-DrugBank.d40.s17.p0
|
Twelve strains of Staphylococcus aureus (a frequent cause of infection in heroin, but not in pentazocine and tripelennamine, addicts) were completely inhibited by the drug combination.
|
pentazocine
|
tripelennamine
|
EFFECT
|
3918122.xml
|
DDI-MedLine.d45.s5
|
DDI-MedLine.d45.s5.p2
|
Patients taking REVIA may not benefit from opioid containing medicines, such as cough and cold preparations, antidiarrheal preparations, and opioid analgesics.
|
REVIA
|
opioid
|
EFFECT
|
Naltrexone_ddi.xml
|
DDI-DrugBank.d346.s4
|
DDI-DrugBank.d346.s4.p0
|
Acetazolamide may elevate cyclosporine levels.
|
Acetazolamide
|
cyclosporine
|
MECHANISM
|
Acetazolamide_ddi.xml
|
DDI-DrugBank.d368.s14
|
DDI-DrugBank.d368.s14.p0
|
Furosemide: TORADOL IV/IM reduced the diuretic response to furosemide in normovolemic healthy subjects by approximately 20% (mean sodium and urinary output decreased 17%).
|
TORADOL
|
furosemide
|
EFFECT
|
Ketorolac_ddi.xml
|
DDI-DrugBank.d3.s8
|
DDI-DrugBank.d3.s8.p4
|
Therefore, co-administration of tricyclic antidepressants with other drugs that are metabolized by this isoenzyme, including other antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (eg, propafenone, flecainide, and encainide), or that inhibit this enzyme (eg, quinidine), should be approached with caution.
|
tricyclic antidepressants
|
encainide
|
ADVISE
|
Nortriptyline_ddi.xml
|
DDI-DrugBank.d202.s16
|
DDI-DrugBank.d202.s16.p6
|
Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
|
Kaletra
|
morphine
|
NONE
|
Etonogestrel_ddi.xml
|
DDI-DrugBank.d484.s0
|
DDI-DrugBank.d484.s0.p872
|
Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
|
erythromycin
|
valproate
|
NONE
|
Carbamazepine_ddi.xml
|
DDI-DrugBank.d94.s4
|
DDI-DrugBank.d94.s4.p212
|
Drugs that may decrease dasatinib plasma concentrations CYP3A4 Inducers: Drugs that induce CYP3A4 activity may decrease dasatinib plasma concentrations.
|
dasatinib
|
dasatinib
|
NONE
|
Dasatinib_ddi.xml
|
DDI-DrugBank.d48.s3
|
DDI-DrugBank.d48.s3.p0
|
Warfarin: Quinolones, including enoxacin, decrease the clearance of R-warfarin, the less active isomer of racemic warfarin.
|
Quinolones
|
R-warfarin
|
MECHANISM
|
Enoxacin_ddi.xml
|
DDI-DrugBank.d395.s23
|
DDI-DrugBank.d395.s23.p5
|
Antifungals: In vitro and/or in vivo data indicate that fluconazole, itraconazole, and oral ketoconazole markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.
|
itraconazole
|
cisapride
|
MECHANISM
|
Cisapride_ddi.xml
|
DDI-DrugBank.d237.s7
|
DDI-DrugBank.d237.s7.p10
|
Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
|
Etonogestrel
|
Lipitor
|
INT
|
Etonogestrel_ddi.xml
|
DDI-DrugBank.d484.s0
|
DDI-DrugBank.d484.s0.p17
|
Concurrent administration of drugs possessing nephrotoxic (e.g., aminoglycosides, indomethacin), myelotoxic (e.g., cytotoxic chemotherapy), cardiotoxic (e.g., doxorubicin) or hepatotoxic (e.g., methotrexate, asparaginase) effects with PROLEUKIN may increase toxicity in these organ systems.
|
cytotoxic
|
PROLEUKIN
|
EFFECT
|
Aldesleukin_ddi.xml
|
DDI-DrugBank.d114.s2
|
DDI-DrugBank.d114.s2.p14
|
Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
|
EQUETROTM
|
cyclosporin
|
MECHANISM
|
Carbamazepine_ddi.xml
|
DDI-DrugBank.d94.s11
|
DDI-DrugBank.d94.s11.p9
|
The benzodiazepines, including alprazolam, produce additive CNS depressant effects when co-administered with other psychotropic medications, anticonvulsants, antihistaminics, ethanol, and other drugs which themselves produce CNS depression.
|
alprazolam
|
psychotropic medications
|
EFFECT
|
Alprazolam_ddi.xml
|
DDI-DrugBank.d131.s0
|
DDI-DrugBank.d131.s0.p5
|
Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.
|
Chlorotrianisene
|
calcium
|
INT
|
Chlorotrianisene_ddi.xml
|
DDI-DrugBank.d446.s0
|
DDI-DrugBank.d446.s0.p4
|
- Indomethacin: Indomethacin blunts the increases in urine volume and sodium excretion seen during bumetanide treatment and inhibits the bumetanide-induced increase in plasma renin activity.
|
Indomethacin
|
bumetanide
|
MECHANISM
|
Bumetanide_ddi.xml
|
DDI-DrugBank.d331.s7
|
DDI-DrugBank.d331.s7.p3
|
Quinolones, including cinoxacin, may enhance the effects of oral anticoagulants, such as warfarin or its derivatives.
|
cinoxacin
|
warfarin
|
EFFECT
|
Cinoxacin_ddi.xml
|
DDI-DrugBank.d562.s8
|
DDI-DrugBank.d562.s8.p4
|
Cholestyramine: Cholestyramine may increase the clearance of corticosteroids.
|
Cholestyramine
|
corticosteroids
|
MECHANISM
|
Dexamethasone_ddi.xml
|
DDI-DrugBank.d314.s10
|
DDI-DrugBank.d314.s10.p2
|
Close supervision and careful adjustment of the dosage are required when nortriptyline hydrochloride is used with other anticholinergic drugs or sympathomimetic drugs.
|
nortriptyline hydrochloride
|
anticholinergic drugs
|
ADVISE
|
Nortriptyline_ddi.xml
|
DDI-DrugBank.d202.s9
|
DDI-DrugBank.d202.s9.p0
|
Although a 3-day regimen of Aprepitant given concomitantly with oral contraceptives has not been studied, alternative or back-up methods of contraception should be used.
|
Aprepitant
|
contraceptives
|
ADVISE
|
Aprepitant_ddi.xml
|
DDI-DrugBank.d382.s21
|
DDI-DrugBank.d382.s21.p0
|
The concomitant administration of uricosuric agents and allopurinol has been associated with a decrease in the excretion of oxypurines (hypoxanthine and xanthine) and an increase in urinary uric acid excretion compared with that observed with allopurinol alone.
|
uricosuric agents
|
allopurinol
|
MECHANISM
|
Allopurinol_ddi.xml
|
DDI-DrugBank.d413.s10
|
DDI-DrugBank.d413.s10.p0
|
Sulfapyridine may interact with any of the following: - Acetaminophen (e.g., Tylenol) (with long-term, high-dose use) or
|
Sulfapyridine
|
Tylenol
|
INT
|
Sulfapyridine_ddi.xml
|
DDI-DrugBank.d179.s1
|
DDI-DrugBank.d179.s1.p1
|
Iron Supplements and Foods Fortified With Iron Concomitant administration of cefdinir with a therapeutic iron supplement containing 60 mg of elemental iron (as FeSO4) or vitamins supplemented with 10 mg of elemental iron reduced extent of absorption by 80% and 31%, respectively.
|
cefdinir
|
iron supplement
|
NONE
|
Cefdinir_ddi.xml
|
DDI-DrugBank.d420.s5
|
DDI-DrugBank.d420.s5.p11
|
Possible drug interactions of HUMORSOL with succinylcholine or with other anticholinesterase agents.
|
HUMORSOL
|
succinylcholine
|
INT
|
Demecarium bromide_ddi.xml
|
DDI-DrugBank.d149.s0
|
DDI-DrugBank.d149.s0.p0
|
Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
|
anticoagulant
|
chymotrypsin
|
EFFECT
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s87
|
DDI-DrugBank.d64.s87.p9
|
ADL-8-2698 is a novel peripherally restricted opioid antagonist that may selectively prevent opioid-induced gastrointestinal effects without reversing analgesia.
|
ADL-8-2698
|
opioid
|
EFFECT
|
11180040.xml
|
DDI-MedLine.d87.s1
|
DDI-MedLine.d87.s1.p1
|
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
|
NUROMAX
|
lithium
|
EFFECT
|
Doxacurium chloride_ddi.xml
|
DDI-DrugBank.d267.s5
|
DDI-DrugBank.d267.s5.p10
|
Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain narcotic analgesics such as meperidine, the phenothiazines and other antipsychotics, tricyclic antidepressants, certain antiarrhythmics such as the quinidine salts, and antihistamines.
|
AKINETON
|
narcotic analgesics
|
EFFECT
|
Biperiden_ddi.xml
|
DDI-DrugBank.d401.s0
|
DDI-DrugBank.d401.s0.p9
|
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.